Security record · archived quarter
NEO
NeoGenomics, Inc. · Healthcare · Medical - Diagnostics & Research
1Tracked holders
0Δ holders
41.34KShares held
$662,315Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 41.34K | $662,315 | n/a | n/a |
| Q2 2026 | 96 | +7 | 89.82M | $1.31B | +13 | −6 |
| Q1 2026 | 92 | +1 | 80.37M | $596.13M | +7 | −6 |
| Q4 2025 | 90 | +1 | 81.69M | $948.79M | +1 | n/a |
| Q3 2025 | 14 | 0 | 59.68M | $460.71M | n/a | n/a |
| Q2 2025 | 11 | 0 | 47.11M | $344.36M | +2 | −2 |
| Q1 2025 | 8 | 0 | 15.46M | $146.75M | +2 | −2 |
| Q4 2024 | 8 | 0 | 10.24M | $168.75M | n/a | n/a |
| Q3 2024 | 7 | 0 | 4.10M | $60.43M | +2 | −2 |
| Q2 2024 | 7 | n/a | 5.49M | $76.11M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 41.34K | +1.0% | $662,315 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 66.00K shares, $60,522 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: First Light Asset Management, LLC
Jul 30
SC 13G: FIRST TRUST PORTFOLIOS LP
Jul 30
SC 13G/A: BlackRock, Inc.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API